Bone Common Stock Shares Outstanding vs Net Receivables Analysis

BBLG Stock

USD 1.88 0.32 14.55%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Common Stock Shares Outstanding and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Common Stock Shares Outstanding vs Net Receivables

Common Stock Shares Outstanding vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Common Stock Shares Outstanding account and Net Receivables. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Bone Biologics' Common Stock Shares Outstanding and Net Receivables is -0.52. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Common Stock Shares Outstanding and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Bone Biologics Corp are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Common Stock Shares Outstanding i.e., Bone Biologics' Common Stock Shares Outstanding and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.52

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Net Receivables

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Bone Biologics' Enterprise Value Over EBITDA is most likely to increase significantly in the upcoming years. The Bone Biologics' current Enterprise Value Multiple is estimated to increase to 0.20, while Selling General Administrative is projected to decrease to roughly 2 M.

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Net Receivables	Non Current Liabilities Total	Inventory	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.42	-0.39	-0.49	-0.34	0.24	0.67	-0.63	-0.51	-0.56	-0.74	-0.39	-0.33	-0.02	-0.2	-0.42	-0.52	-0.08	0.66	-0.15	0.67	-0.51	-0.23
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.24	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.7	-0.93	0.34	-0.23	0.18	0.81	-0.06	-0.23	-0.14	0.03	-0.8
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.23	0.73	-0.29	0.46	0.39	-0.57	-0.47	0.44	-0.38	0.43	0.94
Cash And Short Term Investments	-0.42	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.16	0.4	0.19	0.58	0.54	-0.16	-0.62	0.58	-0.48	0.56	0.64
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.24	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	0.0	0.18	0.02	0.43	0.47	-0.02	-0.7	0.07	-0.59	0.35	0.56
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.24	0.68	0.46	0.38	0.28	0.71	-0.48	0.52	-0.06	0.41	0.31	-0.31	0.16	-0.34	0.32	-0.31
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.7	0.93	-0.36	0.19	-0.23	-0.82	0.13	0.23	0.2	-0.07	0.77
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.39	-0.24	-0.3	-0.76	-0.83	0.05	0.94	-0.5	0.97	-0.89	-0.46
Other Stockholder Equity	-0.63	0.59	-0.12	0.62	0.66	0.59	0.6	0.24	0.06	-0.96		0.23	0.26	0.93	0.74	0.3	0.33	0.22	0.73	0.84	-0.14	-0.92	0.6	-0.92	0.91	0.61
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.74	-0.76	0.32	0.02	0.45	0.72	-0.4	-0.09	-0.45	0.29	-0.49
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.44	-0.63	0.18	0.0	0.44	0.6	-0.4	-0.27	-0.48	0.23	-0.3
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.46	0.18	0.29	0.71	0.78	0.03	-0.9	0.55	-0.88	0.84	0.44
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		0.09	0.55	0.33	0.77	0.54	-0.25	-0.71	0.61	-0.59	0.63	0.66
Short Term Debt	-0.33	-0.24	0.7	-0.23	0.16	-0.24	0.0	0.71	-0.7	-0.39	0.3	0.74	0.44	0.46	0.09		-0.58	0.21	0.11	0.55	0.53	-0.42	0.41	-0.39	0.47	-0.34
Net Tangible Assets	-0.02	0.72	-0.93	0.73	0.4	0.72	0.18	-0.48	0.93	-0.24	0.33	-0.76	-0.63	0.18	0.55	-0.58		-0.18	0.44	-0.06	-0.83	-0.15	0.31	-0.09	0.15	0.83
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.21	-0.18		0.31	0.09	0.33	-0.25	0.07	-0.29	0.22	-0.33
Long Term Debt	-0.42	0.44	-0.23	0.46	0.58	0.44	0.43	-0.06	0.19	-0.76	0.73	0.02	0.0	0.71	0.77	0.11	0.44	0.31		0.51	0.07	-0.77	0.53	-0.67	0.63	0.47
Net Receivables	-0.52	0.32	0.18	0.39	0.54	0.32	0.47	0.41	-0.23	-0.83	0.84	0.45	0.44	0.78	0.54	0.55	-0.06	0.09	0.51		0.15	-0.8	0.57	-0.84	0.91	0.36
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.53	-0.83	0.33	0.07	0.15		-0.1	-0.12	-0.06	0.0	-0.69
Inventory	0.66	-0.45	-0.06	-0.47	-0.62	-0.45	-0.7	-0.31	0.13	0.94	-0.92	-0.4	-0.4	-0.9	-0.71	-0.42	-0.15	-0.25	-0.77	-0.8	-0.1		-0.46	0.95	-0.82	-0.45
Short Long Term Debt	-0.15	0.39	-0.23	0.44	0.58	0.39	0.07	0.16	0.23	-0.5	0.6	-0.09	-0.27	0.55	0.61	0.41	0.31	0.07	0.53	0.57	-0.12	-0.46		-0.33	0.75	0.44
Property Plant Equipment	0.67	-0.35	-0.14	-0.38	-0.48	-0.35	-0.59	-0.34	0.2	0.97	-0.92	-0.45	-0.48	-0.88	-0.59	-0.39	-0.09	-0.29	-0.67	-0.84	-0.06	0.95	-0.33		-0.82	-0.37
Current Deferred Revenue	-0.51	0.38	0.03	0.43	0.56	0.38	0.35	0.32	-0.07	-0.89	0.91	0.29	0.23	0.84	0.63	0.47	0.15	0.22	0.63	0.91	0.0	-0.82	0.75	-0.82		0.43
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.34	0.83	-0.33	0.47	0.36	-0.69	-0.45	0.44	-0.37	0.43

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	12.1K	18.9K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	1.0M	30.8K	6.7M	8.5M	3.7M	2.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Net Tangible Assets	(8.6M)	(11.9M)	(13.7M)	6.6M	7.6M	7.9M
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	8.2M	0.0	11.3M	12.2M	99.9K	888.46
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Currently Active Assets on Macroaxis

C	Citigroup
CRM	Salesforce
MSFT	Microsoft
V	Visa Class A
GOOG	Alphabet Inc Class C

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:

How To Invest In Bone

Details

Is Bone Stock a good investment?

Details

What is Bone Biologics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Bone Stock analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation

Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(34.01)

Return On Assets

(0.85)

Return On Equity

(1.89)

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Common Stock Shares Outstanding vs Net Receivables Analysis

Common Stock Shares Outstanding vs Net Receivables

Common Stock Shares Outstanding vs Net Receivables Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Net Receivables

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Bone Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.97	Retained Earnings
Property Plant Equipment	+ 0.95	Inventory
Net Invested Capital	+ 0.94	Cash

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Property Plant Equipment	- 0.92	Other Stockholder Equity
Inventory	- 0.92	Other Stockholder Equity